FDA declines to approve Daiichi Sankyo's blood cancer treatment

(Reuters) - Japan's Daiichi Sankyo Co said on Friday the U.S. Food and Drug Administration has declined to approve its drug quizartinib as a treatment for adults with a type of blood cancer. The decision follows an advisory committee meeting, held in May, where independent advisers to the U.S.

Reuters June 22, 2019 01:06:59 IST
FDA declines to approve Daiichi Sankyo's blood cancer treatment

FDA declines to approve Daiichi Sankyos blood cancer treatment

(Reuters) - Japan's Daiichi Sankyo Co said on Friday the U.S. Food and Drug Administration has declined to approve its drug quizartinib as a treatment for adults with a type of blood cancer.

The decision follows an advisory committee meeting, held in May, where independent advisers to the U.S. regulator voted 8-3 against the drug's approval to treat acute myeloid leukemia patients with a specific genetic mutation called FLT3.

Several experts in the committee concurred that the data presented by the company was not strong enough to support an approval and called for further study.

Daiichi said it would evaluate FDA's complete response letter as well as determine next steps in the United States.

Quizartinib has only been approved for use in Japan.

Daiichi has been focusing on building its cancer drug franchise and is targeting a whopping 500 billion yen ($4.65 billion) in annual sales from the business in fiscal 2025 from 20 billion yen in 2017.

A second drug from the company, pexidartinib, that aims to treat a type of rare, non-cancerous tumor that usually affects joints and limbs is still under FDA review.

($1 = 107.4800 yen)

(Reporting by Tamara Mathias in Bengaluru; Editing by Shinjini Ganguli)

This story has not been edited by Firstpost staff and is generated by auto-feed.

Updated Date:

TAGS:

also read

France, Germany to agree to NATO role against Islamic State - sources
| Reuters
World

France, Germany to agree to NATO role against Islamic State - sources | Reuters

By Robin Emmott and John Irish | BRUSSELS/PARIS BRUSSELS/PARIS France and Germany will agree to a U.S. plan for NATO to take a bigger role in the fight against Islamic militants at a meeting with President Donald Trump on Thursday, but insist the move is purely symbolic, four senior European diplomats said.The decision to allow the North Atlantic Treaty Organization to join the coalition against Islamic State in Syria and Iraq follows weeks of pressure on the two allies, who are wary of NATO confronting Russia in Syria and of alienating Arab countries who see NATO as pushing a pro-Western agenda."NATO as an institution will join the coalition," said one senior diplomat involved in the discussions. "The question is whether this just a symbolic gesture to the United States

China's Xi says navy should become world class
| Reuters
World

China's Xi says navy should become world class | Reuters

BEIJING Chinese President Xi Jinping on Wednesday called for greater efforts to make the country's navy a world class one, strong in operations on, below and above the surface, as it steps up its ability to project power far from its shores.China's navy has taken an increasingly prominent role in recent months, with a rising star admiral taking command, its first aircraft carrier sailing around self-ruled Taiwan and a new aircraft carrier launched last month.With President Donald Trump promising a US shipbuilding spree and unnerving Beijing with his unpredictable approach on hot button issues including Taiwan and the South and East China Seas, China is pushing to narrow the gap with the U.S. Navy.Inspecting navy headquarters, Xi said the navy should "aim for the top ranks in the world", the Defence Ministry said in a statement about his visit."Building a strong and modern navy is an important mark of a top ranking global military," the ministry paraphrased Xi as saying.